• Markel Group Inc. has reported its fourth-quarter 2025 results, with revenue rising to US$4,007.97 million and net income reaching US$576.81 million, while full-year net income came in at US$2.11 billion.
• Despite lower full-year earnings per share from continuing operations, the company delivered higher quarterly EPS than a year ago, highlighting a strong finish to 2025.
• With quarterly earnings per share from continuing operations improving year on year, we’ll examine how this shapes Markel Group’s investment narrative.

Find companies with promising cash flow potential yet trading below their fair value.

What Is Markel Group's Investment Narrative?

To own Markel Group, you really need to be comfortable with a hybrid story of specialty insurance and long-term investing, where periodic earnings swings are part of the package. The latest quarter fits that picture: Q4 2025 delivered higher revenue and sharply improved earnings per share from continuing operations compared with a year ago, yet full-year net income and EPS declined, reminding investors that results can be lumpy. In the short term, a strong finish to the year may ease concerns after softer earlier quarters and support confidence in management’s capital allocation, especially following sizeable share buybacks and the preferred share redemption. That said, the full-year earnings drop, lower profit margins and a valuation above peer P/E multiples keep execution risk and pricing power firmly in focus, even after this solid quarter.

However, one earnings-driven risk is still front and center that investors should not overlook. Markel Group's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Five Simply Wall St Community valuations span roughly US$1,476 to a very large US$4,503, showing wide disagreement on Markel’s worth. Set against a strong Q4 but weaker full-year trend, this spread underlines how differently investors may weigh recent earnings volatility and margin pressure when thinking about the company’s future performance.

Explore 5 other fair value estimates on Markel Group - why the stock might be worth 28% less than the current price!

Build Your Own Markel Group Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Markel Group research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Markel Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Markel Group's overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• We've found 11 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• AI is about to change healthcare. These 105 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.